Friday, November 20, 2026
Breaking
Health

FG Backs Lafia Centre’s Lassa Fever Vaccine Development Drive

Advertisement

LAFIA, NIGERIA — The Federal Government has pledged support for efforts by the Federal University Teaching Hospital (FUTH), Lafia, Nasarawa State, to develop a locally produced vaccine against Lassa fever, as Nigeria intensifies efforts to strengthen its capacity to prevent and respond to the deadly viral disease.

The Coordinating Minister of Health and Social Welfare, Professor Muhammad Ali Pate, gave the assurance on Friday, November 20, 2026, during an inspection of facilities at the Centre for Vaccine Research and Biotechnology located within the teaching hospital.

Pate said the government was impressed by the centre’s facilities, the leadership of FUTH’s Chief Medical Director, Dr Hassan Ikrama, and the commitment of researchers working to develop vaccine solutions for diseases affecting Nigeria.

He disclosed that the centre already had vaccine candidates at early stages of development, describing their initial prospects as encouraging. He pledged that the Federal Government would continue supporting the initiative, including by facilitating partnerships with internationally experienced institutions.

The minister also said the government would help strengthen the centre’s infrastructure and equipment, while creating opportunities for its researchers and technical personnel to acquire expertise and learn from established global institutions.

According to him, developing vaccines that address Nigeria’s specific health challenges is essential to improving public health outcomes and reducing the country’s dependence on imported medical products.

Pate commended the Nasarawa State Government, the hospital’s management and researchers from collaborating institutions for their contributions to establishing the research facility. He said the initiative could strengthen Nigeria’s capacity to respond to infectious diseases through locally driven scientific research.

Dr Ikrama, in his response, welcomed the minister’s visit and described the Federal Government’s commitment as an important boost to the hospital’s research programme.

He said the hospital remained committed to providing institutional support and an enabling environment for the centre to advance medical research, innovation and the development of practical solutions to public health challenges.

Advertisement

The initiative builds on earlier efforts to establish Lafia as a centre for vaccine research. In May 2025, FUTH announced plans to lead a vaccine research and development hub focused on Lassa fever and other infectious disease threats. The project brought together researchers and stakeholders, including vaccine development specialist Dr Simon Agwale and other institutions.

In November 2025, FUTH also signed a memorandum of understanding with the National Institute for Pharmaceutical Research and Development to advance vaccine research. The partnership was expected to combine the institute’s pharmaceutical research expertise with the teaching hospital’s clinical facilities, laboratory services and access to study participants.

Lassa fever remains a major public health concern in Nigeria. The Nigeria Centre for Disease Control and Prevention reported 1,186 confirmed cases and 272 deaths cumulatively by epidemiological week 44, covering October 26 to November 1, 2026. The cases were recorded across 24 states and 119 local government areas, underlining the continuing burden of the disease. The reported case fatality rate stood at 23 per cent.

The disease is primarily transmitted to humans through contact with food or household items contaminated by the urine or droppings of infected multimammate rats. Human-to-human transmission can also occur, particularly in healthcare settings where infection prevention measures are inadequate.

Although early diagnosis and prompt medical treatment can improve outcomes, the absence of a widely available approved vaccine has made prevention, surveillance and effective clinical management central to Nigeria’s response.

The National Lassa Fever Strategic Plan for 2026–2030 identifies vaccine development, clinical trials and regulatory approval as national priorities. It sets an objective of having at least one vaccine candidate approved by 2030, while emphasising the need for research funding, stronger institutional capacity and international collaboration.

The Lafia project therefore represents part of a wider national effort to build local scientific expertise and reduce reliance on external vaccine development.

However, the development of a vaccine remains a lengthy scientific process. Early-stage candidates must undergo laboratory assessment, preclinical studies and successive clinical trials to establish their safety, effectiveness and suitability for regulatory approval.

The Federal Government’s pledge is consequently an important commitment to research support, rather than confirmation that a vaccine is ready for public use.

If sustained funding, technical partnerships and the necessary research infrastructure are secured, the Lafia centre could contribute to Nigeria’s long-term efforts to develop vaccines against Lassa fever and other infectious diseases.

Advertisement
Got News? Report it to DDM. Send a tip